Parkinson’s Disease is under clinical development by Notitia Biotechnologies and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Parkinson’s Disease’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Parkinson’s Disease overview
The drug candidate is under development for the treatment of Parkinson's disease. The drug candidate is consortia of bacteria being developed based on foundation guild microbiome platform.
Notitia Biotechnologies overview
Notitia Biotechnologies is a biotechnology company that creates a platform for the study and discovery of microbiome data using a novel approach. The company is Headquartered in United States.
For a complete picture of Parkinson’s Disease’s drug-specific PTSR and LoA scores, buy the report here.